Clinical Trials Browser

Carcinoma, Hepatocellular, Liver Neoplasms

Locally Advanced Rectal Cancer

Esophageal Squamous Cell Carcinoma

Pancreatic Neoplasms

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Turcot syndrome, Colorectal Neoplasms

Colonic Neoplasms

Biliary Tract Neoplasms

Colorectal Neoplasms

Esophageal Neoplasms

Esophageal Squamous Cell Carcinoma

Locally Advanced Rectal Cancer

Stomach Neoplasms

Early Low Rectal Cancer

Rectal Neoplasms

Gallbladder Neoplasms, Klatskin Tumor

Anal Canal Carcinoma, Anus Neoplasms

Rectal Neoplasms

Microsatellite Stable Metastatic Colorectal Cancer

Adenocarcinoma of the Stomach

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Microsatellite Stable Metastatic Colorectal Cancer

Stomach Neoplasms

Early Low Rectal Cancer

Rectal Neoplasms

Chemotherapy

DMMR Colorectal Cancer

Biliary Tract Neoplasms Immunotherapy

Advanced Pancreatic Cancer

Esophageal Squamous Cell Carcinoma

Neoplasm Metastasis, Stomach Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Pancreatic Neoplasms

Esophageal Neoplasms

Stomach Neoplasms

Carcinoma, Hepatocellular

Adenocarcinoma of the Stomach

Colorectal Neoplasms

Advanced Biliary Tract Cancer

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Biliary Tract Neoplasms, Liver Neoplasms

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Carcinoma, Hepatocellular

Rectal Neoplasms

Esophageal Squamous Cell Carcinoma

Clinical Trials

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

TORCH-iTNT

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

PICC

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

ONTOP

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

PNACGEC

TORCH

TORCH-E

TRACER

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

TORCH-R

SLOT

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

TORCH-E2

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

EC-CRT-007

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

TREE

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer